Navigation Links
Small molecules found to protect cells in multiple models of Parkinson's disease
Date:12/28/2009

FINDINGS: Several structurally similar small molecules appear capable of protecting cells from alpha-synuclein toxicity, a hallmark of Parkinson's disease.

RELEVANCE: Parkinson's disease is a neurodegenerative disorder characterized by tremors, muscle rigidity, and slowed movements. There is currently no cure for the disease, and current Parkinson's therapies only address disease symptoms, not the disease's cellular cause.

Small molecules found to protect cells in multiple models of Parkinson's disease

CAMBRIDGE, Mass. (December 28, 2009) Several structurally similar small molecules appear capable of protecting cells from alpha-synuclein toxicity in multiple models of Parkinson's disease, according to Whitehead Institute researchers. Misfolded copies of the alpha-synuclein protein in brain cells are a hallmark of Parkinson's disease.

"In this research, we used yeast as a Parkinson's disease model system to identify the compounds that really work in two higher order model systems of Parkinson's," says Julie Su, a first co-author on the paper describing the research and a former postdoctoral researcher in Whitehead Member Susan Lindquist's lab. "And that shows that those compounds' targets are highly conserved over a billion years of evolution."

Parkinson's disease is a neurodegenerative disorder characterized by tremors, muscle rigidity, and slowed movements. In the neurons of Parkinson's patients' brains, researchers have noted Lewy bodies, abnormal spheres composed of the protein alpha-synuclein. There is currently no cure for the disease, and current Parkinson's therapies only address disease symptoms, not the disease's cellular cause.

In their article in Disease Models and Mechanisms (DMM), Lindquist scientists report that four related small molecules prevented the development of several cellular traits associated with Parkinson's disease, including the accumulation of alpha-synuclein deposits in the cell, improper protein trafficking from one organelle to another, and damage inflicted on the cells' engines, the mitochondria.

The research is based on a type of brewer's yeast modified to produce too much of the alpha-synuclein protein in its cells. The resulting cells manifest adverse effects similar to those experienced in brain cells from Parkinson's patients.

Using this yeast strain, the Lindquist team screened 115,000 small compounds to see which ones alleviate the Parkinson's-like traits. During a screen, a compound is added to a small amount of yeast. Researchers can then easily and efficiently detect if that compound changes the yeast's growth rate, compared to a control. The technique takes advantage of the yeast's normally fast growth, which allows researchers to quickly test thousands of compounds, a process that is not possible in other frequently-used Parkinson's disease models.

Four compounds were found to restore the alpha-synuclein yeast cells' growth to 50% of normal yeast cells. Yeast cells that were not treated with the compounds died. The four compounds have similar chemical structures, a finding that indicates they may be acting on the same target or targets. The researchers also identified two commercially available compounds with similar chemical structures and used those in further tests.

To determine if the six compounds would work in animal models of Parkinson's, the scientists tested the compounds in the round worm Caenorhabditis elegans and in rat neurons. In both of these disease models, cells overproduce alpha-synuclein resulting in the same deleterious effects as in the yeast model. During testing, the first four compounds were able to rescue the round worms, while in the rat neurons, three of the four original compounds and one of the commercial compounds improved the nerve cells' growth.

In all of the models, the compounds improved protein trafficking and decreased mitochondrial damage.

"Those two things are obviously related," says Pavan Auluck, first co-author and a visiting scientist in the Lindquist lab. "We're trying to figure out what the connections are between them. And there are a number of ways they can be related."

Lindquist agrees: "There are very deeply rooted processes that connect protein trafficking and mitochondrial viability," says Lindquist, who is also a Howard Hughes Medical Institute investigator and a professor of biology at MIT. "That emphasizes that the underlying problem caused by alpha-synuclein is a general cellular defect that is part of the machinery of all eukaryotic cells. The specific problems in Parkinson's are due to the neurons being particularly sensitive to that process going awry."

As for the future of the specific compounds identified in this study, Daniel Tardiff, a Lindquist postdoctoral researcher, remains optimistic.

"Theoretically if a compound is having a beneficial effect on yeast cells, and in a worm, and in primary neurons, then possibly through years and years of work, it might actually be a potential therapeutic avenue or drug," says Tardiff. "Though we started in yeast, one of those compounds could actually have some potential for human health in Parkinson's disease. That's always a lofty goal."


'/>"/>

Contact: Nicole Giese
giese@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Related biology news :

1. Emerald BioStructures announces discovery of small molecule modulators of PDE4
2. Small changes in protein chemistry play large role in Huntingtons disease
3. Research yields new agent for some drug-resistant non-small cell lung cancers
4. Small addition to cancer drug may make big difference
5. Small nanoparticles bring big improvement to medical imaging
6. Small, beautiful and additive-free
7. Small mechanical forces have big impact on embryonic stem cells
8. Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
9. Conservation targets too small to stop extinction
10. Small molecule inhibits pathology associated with myotonic dystrophy type 1
11. Small rodents encourage the formation of scrubland in Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
Breaking Biology Technology: